Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study (PHTS) group

• DOI: 10.1111/petr.12923
• Publication Date: 2017-04-05T17:47:15Z
• Authors: Matthew J. Bock; Elfriede Pahl; Paolo G. Rusconi; Gerard J. Boyle; John J. Parent; Clare J. Twist; James K. Kirklin; Elizabeth Pruitt; Daniel Bernstein
• Keywords: Pediatric cancer

Abstract We aimed to determine whether malignancy after pediatric HT x for ACM affects overall post‐ survival. Patients <18y listed in the PHTS database between 1993 and 2014 were compared those with DCM . A 2:1 matched cohort was also compared. Wait‐list survival, along freedom from common complications, Eighty subjects due , whereas 1985 Although wait‐list survival higher group, lower cohort. Neither difference persisted analysis. Primary cause of death group infection, which than group. Malignancy rates not different. All malignancies PTLD without primary cancer recurrence or SMN Long‐term graft is no different peers, nor there an increased risk any malignancy. However, infection are Further studies needed assess effects prior chemotherapy on susceptibility this